stars 1 stars 2 stars 3

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

AQEMIA Questions

The AQEMIA annual revenue was $12.7 million in 2026.

Maximilien Levesque is the CEO and co-founder of AQEMIA.

67 people are employed at AQEMIA.

AQEMIA is based in Paris, Île-de-France.

Top AQEMIA Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users